March is recognized as Awareness Month for several diseases, including Colorectal Cancer, Cerebral Palsy, Deep Vein Thrombosis, Endometriosis, Essential Tremor, Kidney Cancer, Multiple Sclerosis, and others.Colorectal cancer is often referred to as the “silent killer” because it doesn’t present any noticeable symptoms in its initial stages, which leads to delayed detection until the disease has reached an advanced, irreversible stage. Regular screening, beginning at age 45, is said to be crucial to preventing colorectal cancer.According to the American Cancer Society, about 154,270 people in the U.S. will be diagnosed with colon and rectal cancer in 2025, and 52,900 will die from the disease. Several drugs have been approved by the FDA to treat colorectal cancer. As recently as January of this year, the U.S. regulatory agency approved Amgen’s Lumakras with Vectibix for KRAS G12C-mutated colorectal cancer. The FDA has approved five novel drugs so far this year. Now, let’s take a look at the stocks awaiting FDA decisions in March—decisions that could not only influence stock prices but also bring hope to patients suffering from diseases with no approved treatments.